Table I.
Effect of GLGZD on IL-1β, IL-6, IL-10 and TNF-α levels in serum following MCAO.
| Group | IL-1β (pg/ml) | IL-6 (pg/ml) | IL-10 (pg/ml) | TNF-α (pg/ml) |
|---|---|---|---|---|
| Sham-surgery | 11.894±1.12 | 47.258±3.99 | 11.428±4.90 | 57.425±16.30 |
| Model | 25.822±2.23a | 41.857±11.25a | 113.490±21.29b | 63.187±16.02a |
| GLGZD-1 | 24.200±2.26 | 62.810±9.29d | 55.063±13.30d | 61.341±6.04c |
| GLGZD-2 | 19.430±2.11c | 158.113±30.75d | 38.895±4.90d | 63.081±9.03 |
Values are expressed as the mean ± standard deviation.
a
P<0.05,
b
P<0.01 vs. sham-surgery group;
c
P<0.05,
d
P<0.05 vs. MCAO model group. IL, interleukin; TNF, tumor necrosis factor; MCAO, middle cerebral artery occlusion; GLGZD, Gualou Guizhi decoction; GLGZD-1, rats that were administered 7.2 g/kg GLGZD; GLGZD-2, rats that were administered 14.4 g/kg GLGZD.